This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InfoLogix, RADA Electronic: Volume Movers

Specific terms of the transaction were not disclosed, but the total upfront payment to BioLineRx from Cypress was $30 million with total potential clinical and regulatory milestones of up to $160 million through to approval in the U.S.

BioLineRx also stands to see potential commercial milestones of $85 million, and a potential additional $90 million associated with approval for additional indications in the U.S. or for approval in other countries in North America.

In addition, Cypress will fund all continuing development activities and pay BioLineRx a royalty based on applicable sales. Volume topped 3.3 million shares, compared to the 50-day average daily volume of 283,000.

Exelixis (EXEL) shares fell by 48 cents, or 10.5%, to $4.10 after Bristol-Myers Squibb (BMY) returned the full rights to develop and commercialize the company's XL184 cancer drug, citing pipeline and prioritization decisions.

As part of the decision to return XL184, BMS will make a payment to Exelixis of $17 million. Volume topped 2.38 million shares, compared to the 50-day average daily volume of 1.29 million.

-- Written by Robert Holmes in Boston.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and get more stock ideas and investing advice on our sister site, Stockpickr.com.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
EXEL $5.46 -2.20%
RADA $1.75 0.00%
AAPL $122.77 0.00%
FB $94.20 -2.80%
GOOG $627.26 0.00%

Markets

Chart of I:DJI
DOW 17,568.53 -127.94 -0.73%
S&P 500 2,079.65 -12.01 -0.58%
NASDAQ 5,088.63 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs